A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

Topical steroid withdrawal syndrome may signal a reminder to clinicians to be good stewards of topical treatments, according ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

BeiGene, a global biotech firm that develops cancer medicines, has opened a 400,000-square-foot life sciences facility in ...

Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability. Click for more on Capital Appreciation.

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...

Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...